Literature DB >> 2179230

How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.

T Büchner1, W Hiddemann, G Maschmeyer, W Ludwig, H Löffler, M Nowrousian, C Aul, A Heinecke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179230     DOI: 10.1007/BF01612647

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  11 in total

1.  Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.

Authors:  C Sauter; W Berchtold; M Fopp; A Gratwohl; P Imbach; P Maurice; L Tschopp; V von Fliedner; F Cavalli
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

2.  A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

Authors:  W R Vogler; E F Winton; D S Gordon; M R Raney; B Go; L Meyer
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

3.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

Authors:  K R Rai; J F Holland; O J Glidewell; V Weinberg; K Brunner; J P Obrecht; H D Preisler; I W Nawabi; D Prager; R W Carey; M R Cooper; F Haurani; J L Hutchison; R T Silver; G Falkson; P Wiernik; H C Hoagland; C D Bloomfield; G W James; A Gottlieb; S V Ramanan; J Blom; N I Nissen; A Bank; R R Ellison; F Kung; P Henry; O R McIntyre; S K Kaan
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

4.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

Authors:  J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia.

Authors:  P A Cassileth; C B Begg; J M Bennett; M Bozdech; S B Kahn; C Weiler; J H Glick
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

6.  A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.

Authors:  M Hayat; U Jehn; R Willemze; C Haanen; R Zittoun; M Monconduit; B Lowenberg; P Stryckmans; M Peetermans; F De Cataldo
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

7.  Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

Authors:  H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

8.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.

Authors:  T Büchner; D Urbanitz; W Hiddemann; H Rühl; W D Ludwig; J Fischer; H C Aul; H A Vaupel; R Kuse; G Zeile
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

9.  High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.

Authors:  W Hiddemann; H Kreutzmann; K Straif; W D Ludwig; R Mertelsmann; R Donhuijsen-Ant; E Lengfelder; Z Arlin; T Büchner
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

10.  Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

Authors:  J K Rees; R G Gray; D Swirsky; F G Hayhoe
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

View more
  1 in total

1.  Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.

Authors:  A Heyll; C Aul; F Gogolin; V Runde; D Söhngen; G Meckenstock; H H Wolf; J Zahner; M Burk; M Winkelmann
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.